Boxer Capital’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Boxer Capital’s Portfolio NGM Stock Details NGM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-500,000	Closed	-$535K	–	74
2023 Q3	$535K	Hold	500,000	–	–	0.03%	68
2023 Q2	$1.29M	Hold	500,000	–	–	0.06%	72
2023 Q1	$2.04M	Hold	500,000	–	–	0.1%	66
2022 Q4	$2.51M	Hold	500,000	–	–	0.13%	56
2022 Q3	$6.54M	Hold	500,000	–	–	0.37%	46
2022 Q2	$6.41M	Hold	500,000	–	–	0.41%	47
2022 Q1	$7.63M	Hold	500,000	–	–	0.39%	47
2021 Q4	$8.86M	Hold	500,000	–	–	0.34%	48
2021 Q3	$10.5M	Hold	500,000	–	–	0.37%	59
2021 Q2	$9.86M	Buy	+500,000	New	+$11.7M	0.35%	65

Other funds holding NGM

Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Boxer Capital's NGM Position: Q4 2023 in Review

Boxer Capital sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q4 2023, closing a stake of 500,000 shares — an estimated $535K sold.

Boxer Capital first reported a position in NGM in Q2 2021 and held it in 10 quarters. The position peaked at $10.5M in Q3 2021. 83 funds tracked by Wall St. Rank hold NGM as of Q4 2023.

Boxer Capital reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Boxer Capital sold 500,000 NGM Biopharmaceuticals, Inc. Common Stock shares in Q4 2023, an estimated $535K.
Boxer Capital first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q2 2021 and held it in 10 quarters.
Boxer Capital's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $10.5M in Q3 2021.
83 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q4 2023.

Based on Boxer Capital's 13F filing for Q4 2023, filed 14 Feb 2024.